Prostate Cancer Clinical Consortium Clinical Research Site: Targeted Therapies
Abstract
The Weill Cornell Medical College Prostate Cancer Research Program (WCMC-PCRP) is a Clinical Research Site of the Prostate Cancer Clinical Trials Consortium (PCCTC). The objective of this research is for WCM, together with NYPBMH and CUMC, to participate in the PCCTC as a multisite Clinical Research Site. Our overall aim is to translate our prostate cancer expertise in targeted therapies, PC imaging, immunotherapy, and correlative science into novel therapeutic approaches that can be tested in multi-institutional studies performed within the PCCTC. We intend to bring novel agents and new biomarker-driven trials directly to PC patients, including underrepresented minorities. Our specific aims are 1) to develop and study novel, targeted therapeutics identified through high-quality molecular analyses; 2) to identify effective treatments and biomarkers based on discovery of mechanisms of PC therapy resistance and sensitivity; 3) to advance PC immunotherapeutics based on preclinical investigations; 4) to study PSMA-targeted radionuclide therapy and develop PSMA molecular imaging; and 5) to open up PCCTC studies to underrepresented minorities in Brooklyn and Upper Manhattan.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2019
- Accession Number
- AD1097380
Entities
People
- David Nanus
Organizations
- Weill Cornell Medicine